Antibiotics Market industry Development, Trends by 2028

Based on n drug class, the antibiotics market is segmented into Cephalosporin, Penicillin, Fluoroquinolones, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others.

 The global antibiotics market was valued at US$  44,111.31 million in 2020 and is projected to reach US$  59,253.24 million in 2028; it is expected to grow at a CAGR of 4.0% during 2021–2028.

Based on n drug class, the antibiotics market is segmented into Cephalosporin, Penicillin, Fluoroquinolones, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others. The cephalosporin segment held the largest share of the market in 2020; however the fluoroquinolones segment is anticipated to register the highest CAGR of 5.3% in the market during the forecast period. Additionally, increasing incidence of pneumonia, bloodstream infections, and Urinary Tract Infections (UTI) is expected to increase the demand for carbapenems class of antibiotics in coming years. Moreover, the lower price of generic carbapenem-based antibiotics is expected to result in increased product adoption, thus compelling carbapenem-based antibiotic manufacturers to develop geographical footprint in lower and middle-income countries.

 

The growth of the market is attributed to some of the key factors, such as rising prevalence of bacterial infections and increasing development of generic drugs. However, challenges associated with tedious  and expensive process of antibiotic development and due to coronavirus pandemic are expected to restraint the growth of the market during the forecast years.

 

Pfizer, Inc., Johnson Johnson Services, Inc. (Janssen Pharmaceuticals), Abbott, GlaxoSmithKine Plc, Sanofi, Novartis AG, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, and Astellas Pharma are among the leading companies operating in the antibiotics market. The companies are focused towards the adoption of organic strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in May 2017, Pfizer's launched new antibiotic for multidrug resistant (MDR) infections Zavicefta in the UK and Germany, its first lauch was in EU markets.

Get Sample Copy with Complete TOC and Figures Graphs @ https://www.theinsightpartners.com/sample/TIPRE00003406/

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, chemicals etc.

Contact Us:

Call: +1-646-491-9876

Email: [email protected]

 


soham mane

69 Blog posts

Comments